• People
  • Practices
  • COVID-19 Resources
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Search
  • Biography
  • Education
  • Recent Publications
Profile Picture

John D. W. Partridge

John
Partridge

Partner

CONTACT INFO

jpartridge@gibsondunn.com

TEL:+1 303.298.5931

FAX:+1 303.313.2857

Denver

1801 California Street, Suite 4200, Denver, CO 80202-2642 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

White Collar Defense and Investigations Administrative Law and Regulatory Practice Anti-Corruption & FCPA Class Actions Crisis Management FDA and Health Care False Claims Act/Qui Tam Defense Life Sciences Litigation Securities Enforcement Transnational Litigation

BIOGRAPHY

John Partridge, a Co-Chair of Gibson Dunn’s FDA and Health Care Practice Group and Chambers-ranked white collar defense and government investigations lawyer, focuses on government and internal investigations, white collar defense, and complex litigation for clients in the life science, health care, and technology industries, among others. Mr. Partridge has particular experience with the Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and the Federal Food, Drug, and Cosmetic Act, including defending major corporations in investigations pursued by the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC). In its rankings, Chambers & Partners has reported that Mr. Partridge’s clients regard him as a “smart and strategic tactician,” who is “very responsive and extremely thorough” and “provides sophisticated advice tailored to the particular market.”

Health Care Fraud and Abuse Matters. Mr. Partridge has represented clients in criminal and civil enforcement actions relating to alleged health care fraud and abuse, including actions conducted by DOJ, the U.S. Food and Drug Administration’s Office of Criminal Investigations, the Department of Health and Human Services Office of Inspector General, and State Attorneys General. His substantive experience includes cases involving allegations relating to clinical trials, off-label promotion, sampling practices, importation of regulated products, and anti-kickback issues (such as speaker programs, product and practice support activities, meals and entertainment, and other financial arrangements). Among other current matters, Mr. Partridge is leading the defense of a multinational medical device company in an Anti-Kickback Statute-premised False Claims Act litigation relating to marketing efforts and reimbursement support, as well as a pharmaceutical company in a False Claims Act case based on purported fraud on the U.S. Patent and Trademark Office. Along with colleagues at Gibson Dunn, Mr. Partridge wrote the criminal enforcement and pharmaceutical sampling chapters of PLI’s Pharmaceutical Compliance and Enforcement Answer Book 2021. In 2018, LMG named Mr. Partridge “Best in Life Sciences” among its Americas Rising Stars.

FCPA and International Anti-Corruption Matters. Mr. Partridge has counseled clients in criminal and civil FCPA enforcement actions and anti-corruption and securities fraud investigations. Among other matters, he defended a multinational medical device and pharmaceutical company in parallel DOJ and SEC securities fraud and FCPA investigations relating to the company’s activities in more than a dozen countries in Asia. Previously, he served as a member of an international team of Gibson Dunn lawyers assisting the compliance monitor appointed in connection with one of the largest FCPA settlements to date (Siemens AG). His compliance monitoring work includes activities in Africa, Asia, Europe, and South America.

Compliance Counseling Matters. In addition to advising multiple publicly traded corporations on investigations and litigation relating to potential health care fraud and abuse and FCPA issues, Mr. Partridge regularly counsels clients on the structure and effectiveness of their anti-corruption compliance programs.

Experience. Among other government investigation engagements, Mr. Partridge has counseled clients on:

An Anti-Kickback Statute-premised False Claims Act investigation of a pharmaceutical company’s speaker programs;

A False Claims Act investigated involving an electronic health records company’s interactions with physicians and certifications of its technology;

A False Claims Act investigation involving a medical device company’s alleged off-label promotion of one of its devices;

A False Claims Act investigation involving a medical device company’s alleged efforts to deceive FDA with regard to the severity of a design issue impacting the efficacy of the company’s product;

A False Claims Act investigation involving a pharmaceutical company’s sampling practices;

A False Claims Act investigation involving a Fortune 500 hospital management company (and stemming from an extensive national investigation);

A grand jury investigation focusing on a former customer of a medical device company;

DOJ and SEC investigations relating to medical device and pharmaceutical companies’ interactions with distributors and health care providers in China;

A range of internal investigations in the pharmaceutical, device, and diagnostic industries relating to distributors and health care providers in China;

FCPA investigations relating to a telecommunications company’s operations in China;

FCPA investigations relating to various telecommunications companies’ business in Mexico;

An FCPA investigation relating to payment irregularities in Latin America;

FCPA investigations relating to a client’s business activities in Russia and the Middle East;

An SEC investigation relating to the accounting and disclosures of a for-profit education company; and

An SEC investigation focusing on the work of the independent auditors of a company that allegedly engaged in accounting fraud.

Mr. Partridge also has represented clients in a variety of matters before state and federal courts and at the trial and appellate levels. Among other civil litigation matters, Mr. Partridge has represented:

A dietary supplement company in several putative class actions relating to product labeling issues that raised questions relating to the Federal Food, Drug, and Cosmetic Act.

A pharmaceutical company in a False Claims Act case in federal court based on alleged fraud on the U.S. Patent and Trademark Office and purported product pricing issues tied to the patents at issue.

A pharmaceutical company in a False Claims Act case in federal court based on alleged violations of the Anti-Kickback Statute tied to sampling practices.

A medical device manufacturer in a case involving alleged violations of, among other laws, California’s Unfair Competition Law and False Advertising Law. Mr. Partridge persuaded a California state court to sustain demurrers without leave to amend on federal preemption grounds.

A pharmaceutical company in a False Claims Act case in federal court based on purported violations of the Anti-Kickback Statute relating to product-support services, educational grants, and speaker events.

A large energy company in multiple federal court civil actions aimed at exposing and preventing enforcement of a fraudulently obtained, multi-billion dollar foreign judgment.

A retailer of home improvement and construction products in a series of administrative and trial-level matters in states across the country where the retailer was denied refunds of sales tax payments (including in two trials in state court).

Mr. Partridge also has appellate experience. In addition to appeals associated with certain cases listed above, his appellate matters include:

U.S. ex rel. Polansky v. Executive Health Resources, Inc., No. 21-1052 (S. Ct.), a False Claims Act case relating to the government’s power to dismiss qui tam actions, in which Mr. Partridge was engaged by the Pharmaceutical Research and Manufacturers of America industry association to submit an amicus brief.

Open Door Ministries v. Lipschuetz, No. 14-SC-787 (Colo. 2016), in which Mr. Partridge persuaded the Colorado Supreme Court to reject an intervenor’s argument that a faith-based ministry’s promissory estoppel case against the City and County of Denver was barred by the Colorado Governmental Immunities Act.

Clyma v. Sunoco, Inc., 594 F.3d 777 (10th Cir. 2010), in which the U.S. Court of Appeals for the Tenth Circuit appointed Mr. Partridge as amicus curiae to brief the court on jurisdictional and First Amendment issues raised by a nonparty’s appeal.

While seconded to the Denver City Attorney Office’s Prosecution and Code Enforcement Section, Mr. Partridge tried more than twenty criminal cases to juries or the court.

Committees, Community Involvement, and Recognitions. Mr. Partridge serves as a member of Gibson Dunn’s Pro Bono, Professional Development, and Hiring Committees—and as a Hiring Partner for Gibson Dunn’s Denver office. He also is a member of the Board of Trustees of the Legal Aid Foundation of Colorado, a nonprofit dedicated to supporting access to justice for low-income residents of Colorado. In recognition of his community involvement and professional achievements, he was recognized by the Denver Business Journal as a “40 Under 40” winner in 2019. Chambers & Partners has ranked him in its White Collar Crime and Government Investigations rankings for Colorado each year since 2019.

Education and Clerkship. Mr. Partridge received his J.D., with distinction, from Stanford Law School in 2007. While there, he served as an Executive Editor of the Stanford Law Review and was awarded the Law Review’s Board of Editors’ Award. Mr. Partridge graduated magna cum laude and Phi Beta Kappa from Dartmouth College in 2002 with a B.A. in History and Psychology. Before joining Gibson Dunn, Mr. Partridge clerked for the Honorable David M. Ebel of the United States Court of Appeals for the Tenth Circuit from 2007 to 2008.

Admissions. Mr. Partridge is admitted to practice law in the states of California and Colorado, as well as in the U.S. Courts of Appeal for the Eighth and Tenth Circuits, the U.S. District Courts for the District of Colorado, the Central District of California, and the Northern District of California.

 

EDUCATION

Stanford University - 2007 Juris Doctor

Dartmouth College - 2002 Bachelor of Arts

ADMISSIONS

California Bar

Colorado Bar

RECENT PUBLICATIONS

Client Alert - March 14, 2023 | DOJ Updates Its Guidance on Corporate Compliance Programs
Client Alert - February 8, 2023 | 2022 Year-End False Claims Act Update
Article - August 12, 2022 | Anti-Kickback Circuit Split Holds Implications For Defendants
Client Alert - July 20, 2022 | 2022 Mid-Year False Claims Act Update
Firm News - February 10, 2022 | Nine Partners Named 2022 BTI Client Service All-Stars
Client Alert - February 3, 2022 | 2021 Year-End False Claims Act Update
Article - January 24, 2022 | Safe Harbors (and Other Strategies) for Life Sciences and Healthcare Companies in the International Anti-Corruption Storm
Client Alert - December 13, 2021 | U.S. Strategy on Countering Corruption Signals Focus on Enforcement
Webcasts - October 19, 2021 | Webcast: The False Claims Act – 2021 Update for Drug & Device Manufacturers
Client Alert - July 26, 2021 | 2021 Mid-Year False Claims Act Update
Client Alert - June 17, 2021 | China Constricts Sharing of In-Country Corporate and Personal Data Through New Legislation
Webcasts - May 25, 2021 | Webcast: Private Equity: Government Enforcement Trends – Parts 1 and 2
Webcasts - February 4, 2021 | Webcast: White Collar Enforcement Outlook 2021 – Sanctions/Export Controls, AML and Healthcare Fraud
Client Alert - January 27, 2021 | 2020 Year-End False Claims Act Update
Webcasts - October 22, 2020 | Webcast: The False Claims Act: Updates for Drug & Device Manufacturers
Client Alert - July 17, 2020 | 2020 Mid-Year False Claims Act Update
Client Alert - April 13, 2020 | FDA Round-Up: Overview of Emergency Actions to Expedite the Availability of Medical Products to Combat COVID-19
Client Alert - April 8, 2020 | Fraud in the COVID-19 Age: Examining and Anticipating Changing Enforcement Activity
Client Alert - March 31, 2020 | Implications of COVID-19 Crisis for False Claims Act Compliance
Client Alert - January 31, 2020 | 2019 Year-End False Claims Act Update
Webcasts - October 15, 2019 | Webcast: The False Claims Act – 2019 Mid-Year Update: Health Care and Life Sciences Sector
Client Alert - August 14, 2019 | 2019 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - July 16, 2019 | 2019 Mid-Year False Claims Act Update
Client Alert - May 14, 2019 | Cooperation Credit in False Claims Act Cases: Opportunities and Limitations in DOJ’s New Guidance
Firm News - March 8, 2019 | John Partridge Named to Denver Business Journal’s 40 Under 40
Client Alert - March 7, 2019 | 2018 Year-End FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - February 12, 2019 | 2018 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 9, 2019 | 2018 Year-End False Claims Act Update
Publications - January 3, 2019 | FCPA Liability for Third-Party Conduct: Identifying Pitfalls and Minimizing Risk
Firm News - September 27, 2018 | Three Gibson Dunn Partners Recognized Among Americas Rising Stars
Webcasts - August 29, 2018 | Webcast: The False Claims Act – 2018 Mid-Year Update: Three Industry-Specific Programs
Webcasts - August 22, 2018 | Webcast: The False Claims Act – 2018 Mid-Year Update: Drug and Device Industries
Client Alert - July 26, 2018 | 2018 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - July 11, 2018 | 2018 Mid-Year False Claims Act Update
Client Alert - February 6, 2018 | DOJ Policy Statements Signal Changes in False Claims Act Enforcement
Client Alert - January 23, 2018 | 2017 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2018 | 2017 Year-End False Claims Act Update
Article - November 17, 2017 | Potential FCPA Liability for Third-Party Conduct
Client Alert - September 4, 2017 | 2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers
Client Alert - August 25, 2017 | 2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Webcasts - August 2, 2017 | Webcast: 2017 Mid-Year Update: The False Claims Act and Drug and Device Manufacturers
Client Alert - July 12, 2017 | 2017 Mid-Year False Claims Act Update
Client Alert - February 15, 2017 | 2016 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 12, 2017 | 2016 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2017 | 2016 Year-End False Claims Act Update
Article - October 27, 2016 | FCA Liability after Escobar: Challenges and Opportunities for Device Companies
Webcasts - September 22, 2016 | Webcast: Hot Topics in Fraud and Abuse Enforcement Involving Health Care Providers
Client Alert - August 2, 2016 | 2016 Mid-Year Health Care Compliance and Enforcement Update – Providers
Article - August 1, 2016 | Evaluating U.S. Fraud and Abuse Compliance Controls, Including Corporate Integrity Agreement Provisions, for a Global Anti-Corruption Compliance Program
Client Alert - July 27, 2016 | 2016 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 7, 2016 | 2016 Mid-Year False Claims Act Update
Client Alert - July 5, 2016 | 2016 Mid-Year FCPA Update
Client Alert - February 18, 2016 | 2015 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 19, 2016 | 2015 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 6, 2016 | 2015 Year-End False Claims Act Update
Client Alert - January 4, 2016 | 2015 Year-End FCPA Update
Article - December 31, 2015 | Expanded Enforcement of Federal False Claims Act, RICO, and Antitrust Law Changes the Legal Landscape for Healthcare Providers
Article - October 7, 2015 | Tech Firms Targeted Under False Claims Act
Client Alert - August 13, 2015 | Another Successful Challenge to Restrictions on Off-Label Promotion
Article - August 3, 2015 | RICO Suits Challenge Off-Label Drug Marketing
Client Alert - July 16, 2015 | 2015 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 8, 2015 | 2015 Mid-Year False Claims Act Update
Client Alert - July 6, 2015 | 2015 Mid-Year FCPA Update
Client Alert - January 14, 2015 | 2014 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 14, 2015 | 2014 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 7, 2015 | 2014 Year-End False Claims Act Update
Client Alert - January 5, 2015 | 2014 Year-End FCPA Update
Client Alert - July 9, 2014 | 2014 Mid-Year False Claims Act Update
Client Alert - July 7, 2014 | 2014 Mid-Year FCPA Update
Client Alert - January 6, 2014 | 2013 Year-End FCPA Update
Client Alert - July 8, 2013 | 2013 Mid-Year FCPA Update
Client Alert - March 4, 2013 | In-House Search Warrant Checklist
Client Alert - January 8, 2013 | 2012 Year-End False Claims Act Update
Client Alert - January 2, 2013 | 2012 Year-End FCPA Update
Client Alert - December 4, 2012 | The End of Off-Label Prosecutions? The Second Circuit Rules That a Pharmaceutical Sales Representative’s Criminal Conviction for Off-Label Promotion Violates the First Amendment
Client Alert - November 19, 2012 | Decoding FCPA Enforcement: The U.S. Government Issues Comprehensive Guidance on the Foreign Corrupt Practices Act
Client Alert - July 11, 2011 | 2011 Mid-Year FCPA Update
Client Alert - November 16, 2010 | Do Rankings Matter? Transparency International Issues Its 2010 Corruption Perceptions Index
  • Sitemap
  • Client Extranet
  • Legal Notices
  • Modern Slavery Statement
  • Privacy Policy
  • Cookie Notice
  • Contact Us
©Gibson, Dunn & Crutcher LLP 2023. All rights reserved.
Top
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytics
Cookies that tie into analytics systems, such as Google Analytics, YouTube and Vimeo analytics for embedded video, etc. The following are the cookies installed by the service: _ga, _gid, collect, vuid
Performance
These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The following cookie is installed by the Google Analytics service: _gat
Save & Accept
Powered by CookieYes Logo